Á¦1ȸ ¾È¿°Áõ ½ÉÆ÷Áö¾ö (Çѱ¹Æ÷µµ¸·ÇÐȸ Çѱ¹¿Ü¾ÈºÎÇÐȸ °øµ¿ÁÖ°ü) : 2022-11-13±³À°ÀÏÀÚ : 2022-11-13
±³À°Àå¼Ò : ¼¿ï¼º¸ðº´¿ø ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ
±³À°ÁÖÁ¦ :
(¿Â-¿ÀÇÁº´Çà) Á¦1ȸ ¾È¿°Áõ ½ÉÆ÷Áö¾ö (Çѱ¹Æ÷µµ¸·ÇÐȸ Çѱ¹¿Ü¾ÈºÎÇÐȸ °øµ¿ÁÖ°ü)ÁÖÃÖ±â°ü : ´ëÇѾȰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Çѱ¹Æ÷µµ¸·ÇÐȸ
´ã´çÀÚ : Á¶À翵
¿¬¶ôó : 02-6403-4300
À̸ÞÀÏ :
jyjomtl@naver.com ±³À°Á¾·ù : ¾È°ú
Âü¼®¿¹»óÀοø : 400¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 5 ½Ã°£ 25ºÐ
¼¼ºÎ¼ö°·á : 40,000¿ø
ºñ°í Á¤È¸¿ø Àü¹®ÀÇ : »çÀüµî·Ï ¹«·á, ÇöÀåµî·Ï 40,000¿ø ºñȸ¿ø Àü¹®ÀÇ : »çÀüµî·Ï 30,000¿ø, ÇöÀåµî·Ï 40,000¿ø Àü°øÀÇ : »çÀüµî·Ï 20,000¿ø, ÇöÀåµî·Ï 30,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 08:50~08:55 °³È¸»ç ±è¼±¿õ(¿¬¼¼´ë)
±âŸ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 08:55~09:00 Çѱ¹Æ÷µµ¸·ÇÐȸ Çѱ¹¿Ü¾ÈºÎÇÐȸ ȸÀå´Ô ÀÎ»ç ¸»¾¸ ÇÔµ·ÀÏ ÀÌÇü±Ù(¼º±Õ°ü´ë ¿¬¼¼´ë)
±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 09:00~09:10 A to Z essentials for ocular immunology ÃÖÇõÁø(¼¿ï´ë)
±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 09:10~09:20 Innovative application of regenerative medicine for anterior segment inflammation management ³ª°æ¼±(°¡Å縯´ë)
±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 09:20~09:30 Innovations in drug delivery and novel therapeutics for posterior segment inflammation management ¼ÛÁöÈÆ(¾ÆÁÖ´ë)
±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 09:30~09:40 Ocular fluid biopsy in the omics era: anterior Áö¿ë¿ì(¿¬¼¼´ë)
±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 09:40~09:50 Ocular fluid biopsy in the omics era: posterior ½ÅÁÖ¿µ(¼¿ï´ë)
Åä·Ð 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 09:50~10:05 Discussion -(-)
ÈÞ½Ä 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 10:05~10:20 Break -(-)
±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 10:20~10:30 Viral inflammatory diseases: anterior aspects ±è¼ºÀç(°æ»ó´ë)
±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 10:30~10:40 Viral inflammatory diseases: posterior aspects Áö¿µ¼®(Àü³²´ë)
Åä·Ð 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 10:40~10:45 Discussion -(-)
±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 10:45~10:55 Conjunctival melanoma ±è¼±¿õ(¿¬¼¼´ë)
±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 10:55~11:05 Uveal melanoma À̽±Ô(¿¬¼¼´ë)
Åä·Ð 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 11:05~11:10 Discussion -(-)
±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 11:10~11:20 Uveitis: anterior approach ¹Úö¿ë(µ¿±¹´ë)
±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 11:20~11:30 Uveitis: posterior approach À̹̿¬(°¡Å縯´ë)
Åä·Ð 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 11:30~11:35 Discussion -(-)
ÈÞ½Ä 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 11:35~11:50 Break -(-)
±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 11:50~12:20 Demystifying Viral Anterior Uveitis Soon Phaik Chee(Singapore National Eye Centre)
±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 12:20~12:50 Treatment for Intermediate, Posterior and Panuveitis Jennifer Elizabeth Thorne(Johns Hopkins University)
Åä·Ð 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 12:50~13:00 Discussion -(-)
½Ä»ç 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 13:00~14:00 Lunch -(-)
±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 14:00~14:10 Systemic work-up in uveitis patients; is it always necessary? ½ÅÁÖ¿¬(¿¬¼¼´ë)
±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 14:10~14:20 Management of uveitis before and after cataract surgery Àü·ç¹Î(ÀÌÈ¿©´ë)
±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 14:20~14:30 Surgical management of uveitis Á¶¿µÁØ(Ãæ³²´ë)
±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 14:30~14:40 TASS vs endophthalmitis ±èÀç¿ë(¿ï»ê´ë)
±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 14:40~14:50 How to approach inflammatory diseases in children ÀÌÁÖ¿ë(¿ï»ê´ë)
Åä·Ð 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 14:50~15:05 Discussion -(-)
ÈÞ½Ä 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 15:05~15:20 Break -(-)
±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 15:20~15:30 Outbreak of fungal endophthalmitis: the aftermath ±è¼º¿ì(°í·Á´ë)
±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 15:30~15:40 The application of en face OCT imaging in uveitis ¸¶´ëÁß(ÇѸ²´ë)
±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 15:40~15:50 Prevalence of HCQ Retinopathy and Recommendation on Screening in Rheumatic Patients with Dry Eye Symptoms Á¤Áö¿ø(ÀÎÇÏ´ë)
±³À°½Ã°£ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 15:50~16:00 The alternative faces of macrophage in the ocular surface ±è°æ¿ì(Áß¾Ó´ë)
Åä·Ð 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 16:00~16:10 Discussion -(-)
±âŸ 11-13 ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 16:10~16:15 Æóȸ»ç À̽±Ô(¿¬¼¼´ë)